Communiqués Arcturus Therapeutics Holdings Inc.

Actions

ARCT

US03969T1097

Temps réel estimé Cboe BZX Autres places de cotation 16:29:33 06/06/2024			Varia. 5j.	Varia. 1 janv.
43,51 ^USD	-1,98 %		+13,67 %	+38,73 %

04/06	Un initié d'Arcturus Therapeutics Holdings a vendu des actions pour une valeur de 1 040 234 $, selon un récent dépôt auprès de la SEC	MT
28/05	Arcturus Therapeutics Holdings Inc. annonce un développement positif de son programme sur la fibrose kystique	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program	28/05	BU
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine	20/05	BU
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine	20/05	PR
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences	15/05	BU
Arcturus Therapeutics: Q1 Earnings Snapshot	08/05	AQ
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress	08/05	BU
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024	25/04	BU
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	19/03	PU
Arcturus Therapeutics: Q4 Earnings Snapshot	07/03	AQ
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress	07/03	BU
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	26/02	BU
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis	23/02	AQ
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis	22/02	BU
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024	20/02	BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02	BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster	05/02	PR
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	22/12	AQ
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	21/12	BU
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	21/12	PR
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	04/12	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Arcturus Therapeutics Holdings Inc.

Actions

ARCT

US03969T1097

Communiqués

Filtres